Ditchcarbon
  • Customers
  1. Organizations
  2. AVEO Pharmaceuticals, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 5 months ago

AVEO Pharmaceuticals, Inc.

Company website

AVEO Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2001, the company has made significant strides in developing innovative therapies for cancer treatment, focusing on targeted therapies and biomarker-driven approaches. With a strong presence in major operational regions, AVEO is dedicated to advancing its core products, including the FDA-approved drug FOTIVDA® (tivozanib), which is designed for the treatment of advanced renal cell carcinoma. This unique product stands out due to its selective inhibition of vascular endothelial growth factor (VEGF) receptors, offering a differentiated approach in oncology. AVEO's commitment to research and development has positioned it as a leader in the oncology sector, with notable achievements in clinical trials and partnerships that enhance its market presence. The company continues to strive for excellence in delivering effective cancer therapies to improve patient outcomes.

DitchCarbon Score

How does AVEO Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

62

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

AVEO Pharmaceuticals, Inc.'s score of 62 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

56%

Let us know if this data was useful to you

AVEO Pharmaceuticals, Inc.'s reported carbon emissions

Inherited from LG Chem, Ltd.

AVEO Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of LG Chem, Ltd., which means that any climate commitments or emissions data may be inherited from its parent organisation. As of now, AVEO Pharmaceuticals has not established its own reduction targets or climate pledges. However, it is important to note that the climate initiatives and performance metrics may be influenced by LG Chem, Ltd., which has its own sustainability strategies and targets. Given the lack of specific emissions data and reduction initiatives from AVEO Pharmaceuticals, stakeholders may need to look to LG Chem, Ltd. for insights into the broader climate commitments and performance of the corporate family.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201820192020202120222023
Scope 1
5,317,349,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
Scope 2
3,781,224,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
Scope 3
1,126,063,000
-
0,000,000,000
0,000,000,000
0,000,000,000
00,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. AVEO Pharmaceuticals, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for AVEO Pharmaceuticals, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

AVEO Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 4 hours ago

Best Medical International, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Plus Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Cyclacel Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Aceragen, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.1
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy